FDA Panel Recommends Easing Peptide Restrictions

An FDA advisory committee voted to loosen restrictions on several unapproved peptides, including BPC-157, despite opposition from agency scientists.

The decision, backed by Health Secretary Robert F. Kennedy Jr., could expand access to controversial treatments popular in wellness circles.

The peptides lack strong clinical evidence, raising safety concerns among medical experts.

The vote signals a shift toward more permissive regulation of experimental compounds.